恩帕格利弗洛辛改善了链毒素诱导的高血糖男性鼠的学习和记忆缺陷

相关实验视频

Updated: Jul 16, 2026

12:59

Barnes Maze Testing Strategies with Small and Large Rodent Models

Published on: February 26, 2014

43.9K

Israa H Isawi¹, Nour A Al-Sawalha², Fatema Mahmoud²

¹Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.

Journal of experimental pharmacology

|February 19, 2026

概括

恩帕格利弗洛辛在高血糖大鼠中改善了短期记忆,但对长期记忆和氧化应激的影响很小. 需要进一步的研究来了解它的神经保护机制.

科学领域:

神经科学是一个神经科学.
内分泌学在内分泌学.
药理学药理学是指药理学的学科.

背景情况:

-葡萄糖共运输体2 (SGLT2) 抑制剂,像empagliflozin (Empa) 一样,是抗糖尿病药物.
恩帕已经显示出除了血糖控制之外的抗氧化和抗炎作用.
在大脑中存在SGLT2,高血糖症与认知能力下降有关.

研究的目的:

调查empagliflozin在超血糖的老鼠模型中对学习和记忆的神经保护作用.
探索涉及氧化应激,BDNF和NF-κB的潜在机制.

主要方法:

在雄性Wistar大鼠中使用斯特佐托辛诱导高血糖症.
获得empagliflozin治疗的老鼠.
用放射臂水迷宫来评估认知功能.
测量了海马体的氧化应激标志物,BDNF和NF-κB.

主要成果:

过高血糖的老鼠表现出学习和记忆障碍.
恩帕格利弗洛辛显著改善了短期记忆.
长期记忆的改善是最小的,氧化应激标志物BDNF或NF-κB没有显著变化.

结论:

在高血糖症中,empagliflozin对短期记忆的益处可能涉及除了直接氧化应激减轻之外的其他机制.
氧化应激和炎症在高血糖引起的认知障碍中的作用是复杂的.
需要进一步的研究才能完全阐明empagliflozin的神经保护机制.

关键词:

这就是为什么BDNF是BDNF.在SGLT2中,SGLT2是SGLT2.动物模型动物模型认知障碍是一种认知障碍.在海马体内,海马体

相关概念视频

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...